glp 1 hepatic steatosis Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease Current Status of Glucagon-like Peptide-1

FDA Public Warning: Unapproved GLP1 Products Are Being Sold Online Announced: June 2025 With the rising popularity of semaglutide (Ozempic/Wegovy), tirzepatide, and investigational agents like retatrutide, unauthorized versions are now flooding the internet

Moxit Shah, DM EndocrinologyConsultant Endocrinologist | Ahmedabad Appointment: 9979992797 Introduction For years, people struggling with obesity were told to "eat less and exercise more." While healthy lifestyle changes remain the foundation of weight management, modern science has shown that obesity is a chronic hormonal disease, not simply a lack of willpower

These findings support their use as a valuable adjunctive obesity management medication (OMMs) in post-bariatric care, though long-term adherence and cost-effectiveness require further investigation

Mean TTR decreased by 2.1% (95% CI, -3.7% to -0.6%

PMID: 25973403